Clinical trialNCT00724815CompletedPhase 3Interventional

The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine

SponsorNuPathe Inc.Enrollment530Migraine Disorders

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study was a randomized, parallel group, double-blind, placebo controlled design to compare the efficacy and tolerability of NP101 to a placebo iontophoretic transdermal patch. The primary objective of this study was to assess the proportion of subjects who were headache pain free at two hours after patch activation. Key secondary objectives included: 1. The proportion of subjects who were nausea free at two hours after patch activation. 2. The proportion of subjects who were photophobia free at two hours after patch activation. 3. The proportion of subjects who were phonophobia free at two hours after patch activation.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Mark Pierce, MD
NuPathe Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

34 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Facility name not stated
Phoenix, Arizona, United States
Facility name not stated
Little Rock, Arkansas, United States
Facility name not stated
Newport Beach, California, United States
Facility name not stated
San Francisco, California, United States
Facility name not stated
Santa Monica, California, United States
Facility name not stated
Fairfield, Connecticut, United States
Facility name not stated
Ocala, Florida, United States
Facility name not stated
Palm Beach Gardens, Florida, United States
Facility name not stated
Sunrise, Florida, United States
Facility name not stated
Atlanta, Georgia, United States
Facility name not stated
Columbus, Georgia, United States
Facility name not stated
Decatur, Georgia, United States
Facility name not stated
Savannah, Georgia, United States
Facility name not stated
Chicago, Illinois, United States
Facility name not stated
Ann Arbor, Michigan, United States
Facility name not stated
Kalamazoo, Michigan, United States
Facility name not stated
Springfield, Missouri, United States
Facility name not stated
St Louis, Missouri, United States
Facility name not stated
Mount Vernon, New York, United States
Facility name not stated
Plainview, New York, United States
Facility name not stated
Greensboro, North Carolina, United States
Facility name not stated
West Chester, Ohio, United States
Facility name not stated
Oklahoma City, Oklahoma, United States
Facility name not stated
Philadelphia, Pennsylvania, United States
Facility name not stated
Pittsburgh, Pennsylvania, United States
Facility name not stated
Wynnewood, Pennsylvania, United States
Facility name not stated
Memphis, Tennessee, United States
Facility name not stated
Nashville, Tennessee, United States
Facility name not stated
Dallas, Texas, United States
Facility name not stated
Houston, Texas, United States
Facility name not stated
San Antonio, Texas, United States
Facility name not stated
Alexandria, Virginia, United States
Facility name not stated
Virginia Beach, Virginia, United States
Facility name not stated
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

NP101 - Sumatriptan iontophoretic transdermal patchPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jan 2009
Primary completion: 31 Jul 2009
Completion: 31 Jul 2009
Last update posted: 4 Feb 2016
Registered enrollment: 530
Registry id: NCT00724815

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.